Grifols holds its Extraordinary General Meeting of Shareholders, with over 76% of the company’s share capital represented

Grifols shareholders approve a bonus share issue as a remuneration formula for shareholders

• The capital increase will be achieved through the issue of 16,328,212 new Class B shares charged to voluntary reserves. Each shareholder will receive 1 new Class B share free of charge for every 20 old shares, irrespective of whether they are Class A or Class B shares

• Grifols keeps its commitment to rewarding shareholders while also increasing the liquidity of its shares

• Shareholders approve all proposals submitted

Barcelona, December 4, 2012: The shareholders of Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), the world’s third-largest producer of plasma-derived biological medicines, have approved by a majority a bonus issue of fully paid up shares as a formula for their remuneration. This issuance of new non-voting shares (Class B) was one of the main proposals included on the agenda of the Extraordinary General Meeting held today at the second calling, with the representation of 516 shareholders, owners of 162,570,512 class A shares, representing 76.3% of the voting share capital of the company.

The approval will allow each shareholder to receive free of charge 1 new Class B share for every 20 old shares, irrespective of whether these are Class A or Class B. The share capital increase approved, for a nominal value of 1.63 million euros, will be achieved through the issue and release of 16,328,212 new non-voting shares (Class B) with a nominal value of 0.10 euros each, with no share premium and charged to voluntary reserves.

The votes delegated to the Board of Directors represented 58% of the company’s share capital, evidencing shareholders’ endorsement of all the items on the agenda.

In this respect, shareholders also ratified the possibility to execute, within a maximum term of one year from the approval, a stock split of Grifols Class A and Class B shares in a proportion of 2 new shares for each 1 old share by reducing their nominal value and increasing the number of shares (to be multiplied by two) without changing the company’s share capital total nominal value.
At present, Grifols’ share capital amounts to 117.9 million euros, represented by 213,064,899 ordinary shares (Class A), and 113,499,346 non-voting shares (Class B). Upon completion of the bonus issue Grifols’ share capital will be 119.5 million euros. It will be represented by 213,064,899 ordinary shares (Class A) with a nominal value of 0.50 euros per share, and 129,827,558 non-voting shares (Class B) each with a nominal value of 0.10 euros.

The new shares will also be listed and all Grifols shares will trade on the stock exchange. Specifically, Grifols’ ordinary shares (Class A) are listed on the Spanish Stock Exchange, and they are a component of the main index, Ibex-35 (GRF), and non-voting Grifols shares (Class B) are listed on the Spanish Stock Exchange (GRF.P) and on the NASDAQ (GRFS) via ADR’s (American Depositary Receipts).

**Grifols maintains its commitment to shareholders**

With this second bonus issue, foreseen to be published in BORME (Spanish Official Gazette of the Commercial Registry) on December 10 and executed within 15 days following its publication, Grifols remains committed to reward its shareholders, who demonstrated their confidence in the management of the company and its future by approving, in the last two years, the allocation to voluntary reserves of the full value of the profits earned by the group, amounting to 167.3 thousand euros in 2011 and 63.5 million euros in 2010.

Debt reduction is a priority for Grifols, which maintains its strategy of rapid deleveraging. In this respect, the net financial debt of Grifols at the end of the third quarter of 2012 stood at 2,519.1 million euros, representing a reduction in the leverage ratio to 3.16 times adjusted EBITDA, down from the ratio of 3.55 times for the second quarter of the year, and from 4.34 times in December 2011.

In addition, Grifols is continuing with all its existing investment plans in Spain and the United States. In this respect, capital expenditure (CAPEX) for the period 2012–2015 will total approximately 414.5 million euros, of which around 40% will be spent in Spain.

Despite the need to reinvest profits deriving from the acquisition of Talecris and in order to guarantee organic growth, the group has always been committed to find other formulae for rewarding its shareholders.

However, it remains Grifols intention to resume the payment of cash dividends in the future. The company aims to return to pay-out levels similar to those prior to the acquisition of Talecris.
About Grifols
Grifols, with presence in more than 100 countries, is a global pharmaceutical company specializing in the Hemotherapy sector, the medical discipline that treats disease using blood components. The company's class A shares have been listed on the Spanish Stock Exchange (MCE: GRF) since 2006 and have been part of the Ibex-35 since 2008. In 2011, the company listed non-voting class B shares on the Mercado Continuo (MCE: GRF.P) and in NASDAQ-United States via ADRs (NASDAQ: GRFS).

Grifols is the third company worldwide in plasma protein therapies, in terms of capacity after the recent purchase of Talecris, with a balanced and diversified range of products. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, as a result of on-going investment plans. Grifols is the world leader in plasma collection with 147 plasma donor centers in the United States to ensure a continued and reliable supply of human plasma for the production of plasma therapies. In terms of production capacity (fractionation), Grifols owns and operates several plants in Spain and the United States that allow it to respond to the growing market demand. Grifols' sustained growth will be supported by a strong presence in the United States, Canada and Europe.

DISCLAIMER
The facts and figures contained in this report which do not refer to historical data are “projections and forward-looking statements”. The words and expressions like “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “try to achieve”, “estimate”, “future” and similar expressions, insofar as they are related to Grifols Group, are used to identify projections and forward-looking statements. These expressions reflect the assumptions, hypothesis, expectations and anticipations of the management team at the date of preparation of this report, which are subject to a number of factors that could make the real results differ considerably. The future results of Grifols Group could be affected by events related to its own activity, such as shortages of raw materials for the manufacture of its products, the launch of competitive products or changes in the regulations of markets in which it operates, among others. At the date of preparation of this report Grifols Group has adopted the measures it considers necessary to offset the possible effects of these events. Grifols, S.A. does not assume any obligation to publicly inform, review or update any projections and forward-looking statements to adapt them to facts or circumstances following the preparation of this report, except as specifically required by law.
This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law 24/1988, of July 28, the Royal Decree-Law 5/2005, of March 11, and/or Royal Decree 1310/2005, of November 4, and its implementing regulations.